At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,207 enrolled
Drug / intervention
Tralokinumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist.
In Brief
A Phase 3 clinical trial evaluating Tralokinumab and Placebo for Uncontrolled Asthma. Completed, enrolled 1,207 participants across 243 sites in 15 countries.
Detailed Summary
A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUncontrolled Asthma
CountriesArgentina, Belgium, Bulgaria, Colombia, Germany, Hungary, Peru, Poland, Slovakia, South Korea, Spain, Taiwan, Ukraine, United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartJun 2014
Primary CompletionFeb 2017
Study CompletionJul 2017
TodayJul 2026
First PostedJun 12, 2014
Enrollment StartJun 13, 2014
Primary CompletionFeb 28, 2017
Study CompletionJul 18, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.1 years ago
Interventions
Tralokinumabbiological
Subcutaneous injection
Placeboother
Subcutaneous injection